Keywords: دو بار در روز; Bronchodilator agents; Electrocardiography; GFF MDI; Pulmonary disease; Chronic obstructive; Holter monitoring; QT prolongation; AE; adverse event; AV; atrioventricular; BID; twice daily; BMI; body mass index; bpm; beats per minute; CI; confidence interva
مقالات ISI دو بار در روز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: دو بار در روز; bid; twice daily; CNHSQ; Children's National Health System Questionnaire; EPO; erythropoietin; FeSo4; ferrous sulfate 300 mg tid; IM; intramuscular; IV; intravenous; LAR; long-acting release; NA; not available; OD; once daily; OHQ; Orthostatic Hypotension
Keywords: دو بار در روز; AF; atrial fibrillation; ACT; activated clotting time; aPTT; activated partial thromboplastin time; b.i.d.; twice daily; dTT; diluted thrombin time; ECT; ecarin clotting time; FFP; fresh frozen plasma; FXa; factor X activated; INR; International Normalize
Keywords: دو بار در روز; Light; Omalizumab; Photoprovocation; Solar urticaria; BID; Twice daily; CSU; Chronic spontaneous urticaria; MUD; Minimal urticaria dose; QD; Once daily; SU; Solar urticaria; UVA; Ultraviolet A; UVB; Ultraviolet B; VL; Visible light;
Keywords: دو بار در روز; The trial was registered under NCT02433834 at; http://www.clinicaltrials.gov; Asthma; Co-suspension delivery technology; Glycopyrronium; Inhaled corticosteroid use; Metered dose inhaler; ACQ-5; Asthma Control Questionnaire-5; AE; adverse event; AUC0-3;
Keywords: دو بار در روز; ADAM; advanced dissolution, absorption, and metabolism; AED; antiepileptic drug; AUC; area-under-the-curve; B/P; blood to plasma ratio; BID; twice daily; BMI; body mass index; CBZ; carbamazepine; CLint; intrinsic clearance; CLR; renal clearance; CL; clear
Keywords: دو بار در روز; Aq-CsA; CsA in a micellar solution; AUC; area under the curve; BAK; benzalkonium chloride; bid; twice daily; CKC; cetalkonium chloride; CMC; critical micellar concentration; CsA; cyclosporine A; DDS; drug delivery system; DED; dry eye disease; EDTA; ethyl
Keywords: دو بار در روز; Nausea; Vomiting; Fullness; Bloating; b.i.d; twice daily; DGSSD; Diabetic Gastroparesis Symptom Severity Diary; FDA; US Food and Drug Administration; GCSI-DD; Gastroparesis Cardinal Symptom Index-Daily Diary; GEBT; gastric emptying breath test; PRO; patie
Keywords: دو بار در روز; Heat acclimation; Short term heat acclimation; Heat stress; Twice daily; Thermoregulation; Athletics; Military
Keywords: دو بار در روز; AE; adverse event; ACR; American College of Rheumatology; Apo; apolipoprotein; BID; twice daily; BP; blood pressure; CHF; congestive heart failure; CRP; C-reactive protein; csDMARD; conventional synthetic disease-modifying antirheumatic drug; CV; cardiova
Keywords: دو بار در روز; anticoagulation; bleeding risk; stroke prevention; AF; atrial fibrillation; b.i.d.; twice daily; CKD; chronic kidney disease; ESRD; end-stage renal disease; FDA; Food and Drug Administration; NOAC; non-vitamin K antagonist oral anticoagulant; TTR; time i
Keywords: دو بار در روز; BID; twice daily; CBC; complete blood cell count; CDC; Centers for Disease Control and Prevention; CNS; central nervous system; CYP3A4; cytochrome P450 3A4; DOT; directly observed therapy; DST; drug susceptibility testing; ECG; electrocardiogram; HIV; hum
Keywords: دو بار در روز; empagliflozin; once daily; pharmacodynamics; pharmacokinetic properties; twice daily;
Keywords: دو بار در روز; BCAA; branched-chain amino acids; BID; twice daily; GABA-A; γ-aminobutyric acid type A; HE; hepatic encephalopathy; MELD; Model for End-Stage Liver Disease; NMDA; N-methyl-d-aspartate receptor; q2-q4; every 2-4 hours; ROS; reactive oxygen species; TID; 3
Keywords: دو بار در روز; MEDVAMC; Michael E. DeBakey Veterans Association Medical Center; M.I.N.I.; Mini-International Neuropsychiatric Interview; DSM-IV; Diagnostic and Statistical Manual of Mental Disorders - IV; WAIS-III; Wechsler Adult Intelligence Scale - III; CPT-II; Contin
Keywords: دو بار در روز; AE; adverse event; ANOVA; analysis of varaince; BE; benzoylecgonine; BID; twice daily; BP; blood pressure; DA; dopamine; DÃH; dopamine beta hydroxylase; ECG; electrocardiogram; HR; heart rate; IV; intravenous; NE; norepinepherine; QID; four times daily;
Keywords: دو بار در روز; HCV; hepatitis C virus; DAA(s); direct-acting antiviral agent(s); PI; NS3/4A protease inhibitor; NI; nucleos(t)ide analogue polymerase inhibitor; NNI; non-nucleoside polymerase inhibitor; HTA(s); host-targeting agent(s); QD; one daily; BID; twice daily; T
Keywords: دو بار در روز; ACC; American College of Cardiology; ACCP; American College of Chest Physicians; ASA; acetylsalicylic acid; bid; twice daily; CI; confidence interval; CrCl; creatinine clearance; CT; computed tomography; CTPA; computed tomography pulmonary angiography; CT
Keywords: دو بار در روز; apixaban; bleeding; dabigatran; direct oral anticoagulant; edoxaban; management; pharmacology; rivaroxaban; ACS; acute coronary syndrome; AF; atrial fibrillation; ASA; acetylsalicylic acid; bid; twice daily; CrCl; creatinine clearance; CYP; cytochrome P45
Fatal breakthrough mucormycosis in a multivisceral transplant patient receiving micafungin: Case report and literature review
Keywords: دو بار در روز; bd; twice daily; CMV; cytomegalovirus; CT; computed tomography scan; GvHD; graft-versus-host disease; L-AmB; liposomal amphotericin B; MIC; minimum inhibitory concentration; od; once daily; spp.; species; Antifungal therapy; Micafungin; Mucormycosis; Mult
Use of Elagolix in Gynaecology
Keywords: دو بار در روز; Endometriosis; gonadotropin-releasing hormone; pain; therapeutics; AE; adverse event; BID; twice daily; BMD; bone mineral density; QD; once daily;
Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
Keywords: دو بار در روز; AMPA; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; bid; twice daily; FDA; Food and Drug Administration; OLEx; open-label extension; qam; every morning; qd; once daily; qhs; every night at bedtime; qpm; every evening; SG; secondarily generalized;
Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants
Keywords: دو بار در روز; AF; atrial fibrillation; BID; twice daily; CKD; chronic kidney disease; CL/F; apparent total clearance after oral administration; CrCL; creatinine clearance; CYP3A4; cytochrome P450 3A4; DVT; deep vein thrombosis; eGFR; estimated glomerular filtration rat
The Evolving Face of Myocardial Reperfusion in Acute Coronary Syndromes: A Primer for the Internist
Keywords: دو بار در روز; ACS; acute coronary syndrome; ACT; activated clotting time; ADP; adenosine diphosphate; AHA/ACC; American Heart Association American/College of Cardiology; APTT; activated partial thromboplastin time; AVM; arteriovenous malformation; BID; twice daily; CAB
Novel founder intronic variant in SLC39A14 in two families causing Manganism and potential treatment strategies
Keywords: دو بار در روز; Congenital manganism; SLC39A14; Manganese toxicity; BID; twice daily; CaNa2EDTA; edetate calcium disodium; CBC; complete blood count; cDNA; complementary DNA; dCT; delta cycle threshold; ddCT; double delta cycle threshold; DMSA; dimercaptosuccinic acid; M
Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
Keywords: دو بار در روز; BID; twice daily; CARBO-ETOP; carboplatin-etoposide therapy; CDK; cyclin-dependent kinase; CI; confidence interval; CIS-ETOP; cisplatin-etoposide therapy; DCR; disease control rate; DLT; dose-limiting toxicity; DoR; duration of response; ED-SCLC; extensiv
Review ArticleExtended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism
Keywords: دو بار در روز; ACCP; American College of Chest Physicians; Bid; twice daily; CI; confidence interval; DVT; deep-vein thrombosis; ESC; European Society of Cardiology; LMWH; low-molecular-weight heparin; NICE; National Institute for Health and Care Excellence; NOAC; non-v
Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data
Keywords: دو بار در روز; Rufinamide; Dosing; Antiepileptic drug; Lennox-Gastaut syndrome; Epilepsy; AE; adverse event; AED; antiepileptic drug; AUC; area under the curve; BID; twice daily; Cmax; peak plasma concentration; ECG; electrocardiogram; EEG; electroencephalogram; EMA;
BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity
Keywords: دو بار در روز; MAP kinase-interacting kinase 1; Non-small cell lung cancer; eIF4E; Small molecule kinase inhibitor; Anti-cancer therapy; AML; acute myeloid leukemia; ATP; adenosine triphosphate; BID; twice daily; CDK; cyclin-dependent kinase; DMSO; dimethyl sulfoxide; e
Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents
Keywords: دو بار در روز; AUC; area under curve; BID; twice daily; GLP-1r; glucagon-like-protein-1 receptor; MTC; medullary thyroid carcinoma; PKPD; pharmacokinetics/pharmacodynamics; QW; once weekly; GLP-1r agonists; C-cell carcinogenicity; Pharmacology; PKPD modelling; Predictio
Original ArticlePharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR
Keywords: دو بار در روز; AE; adverse event; AUC; area under the curve; BID; twice daily; CF; cystic fibrosis; CFQ-R; Cystic Fibrosis Questionnaire-Revised; CFTR; cystic fibrosis transmembrane conductance regulator; DDI; drug-drug interaction; ECG; electrocardiogram; ER; endopla
Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder
Keywords: دو بار در روز; Bipolar disorder; Mania; Mixed episodes; Asenapine; Safety; Tolerability; AE; adverse event; ANCOVA; analysis of covariance; ASN; asenapine; ATS; All Treated Set; bid; twice daily; BMI; body mass index; CGI-BP-OS; Clinical Global Impression scale for use
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension⢠Delivery Technology in patients with chronic obstructive pulmonary disease
Keywords: دو بار در روز; COPD; Muscarinic antagonists; β2-agonist; Co-Suspension⢠Delivery Technology; Metered dose inhaler; AE; adverse event; BID; twice daily; CAT; COPD Assessment Test; COPD; chronic obstructive pulmonary disease; CI; confidence interval; DPI; dry powder in
Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options
Keywords: دو بار در روز; Basal insulin; Treatment intensification; Type 2 diabetes mellitus; 4P-MACE; 4-point major adverse cardiovascular events; ADA; American Diabetes Association; AE; adverse event; AUC; area under the glucose curve; BID; twice daily; BMI; body mass index; CHF
Pharmacology and toxicology of α- and β-Asarone: A review of preclinical evidence
Keywords: دو بار در روز; Pharmacokinetics; Pharmacology; Toxicology; α-Asarone; β -Asarone; Aβ; β-amyloid peptides; AChE; Acetylcholinesterase; ATP; adenosine triphosphate; BDNF; brain-derived neurotrophic factor; Bcl; B-cell lymphoma; b.i.d; twice daily; CNS; central nervous
The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update
Keywords: دو بار در روز; bid; twice daily; BP-I/BP-II; bipolar I/II disorder; IM; intramuscular; tid; 3 times daily;
Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation
Keywords: دو بار در روز; AE; adverse event; AI; augmentation index; AUC; area under the curve; BID; twice daily; Cavg; average concentration; Cmax; maximal concentration; mg; milligrams; mL; milliliters; MPI; myocardial performance index; ng; nanograms; PAT; peripheral arterial t
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
Keywords: دو بار در روز; Forced vital capacity; Acute exacerbations; Disease progression; Quality of life; Mortality; bid; twice daily; FGFR; fibroblast growth factor receptor; FVC; forced vital capacity; HR; hazard ratio; IPF; idiopathic pulmonary fibrosis; MedDRA; Medical Dicti
Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients
Keywords: دو بار در روز; Ginkgo biloba extract; Sorafenib; Hepatocellular carcinoma; Metastasis; Chemotherapy; HCC; hepatocellular carcinoma; GBE; Ginkgo biloba extract; MTD; maximum tolerated dose; QD; once daily; BID; twice daily; OS; median overall survival; TTP; time to progr
Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder
Keywords: دو بار در روز; AE; adverse event; AIMS; Abnormal Involuntary Movement Scale; ANCOVA; analysis of covariance; ATS; all-treated set; BARS; Barnes Akathisia Rating Scale; BID; twice daily; CGI-BP-S; Clinical Global Impression Scale-Bipolar Illness-Severity; CI; confidence
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
Keywords: دو بار در روز; cardiovascular outcomes; cardiovascular risk factors; major adverse cardiovascular events psoriasis; tofacitinib; BID; twice daily; BP; blood pressure; CV; cardiovascular; HbA1c; glycated hemoglobin; HDL; high-density lipoprotein; hsCRP; high-sensitivity
Antiviral effect of ranpirnase against Ebola virus
Keywords: دو بار در روز; Ebola (EBOV); Antiviral; Ranpirnase; BID; twice daily; EBOV; Zaire Ebola virus; i.p.; intraperitoneal; IV; intravenous; MOI; multiplicity of infection; pi; post-infection; PFU; plaque forming units; QD; once daily;
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)
Keywords: دو بار در روز; apremilast; nail psoriasis; phosphodiesterase 4 inhibitor; psoriasis; scalp psoriasis; systemic therapy; BID; twice daily; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; NAPSI; Nail Psoriasis Severity Index; NAPSI-50;
Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study
Keywords: دو بار در روز; ANCOVA; analysis of covariance; BCVA; best-corrected visual acuity; BID; twice daily; CFB; change from baseline; CI; confidence interval; IOP; intraocular pressure; ITT; intent-to-treat; LBN; latanoprostene bunod; LOCF; last observation carried forward; l
Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
Keywords: دو بار در روز; Apo; apolipoprotein; BID; twice daily; CV; cardiovascular; CVD; cardiovascular disease; CE; cholesterol ester; CETP; cholesterol ester transfer protein; CRP; C-reactive protein; DAS28; Disease Activity Score with 28 joint-count; DMARD; disease-modifying a
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues
Keywords: دو بار در روز; Apoptosis; Drug safety; Imatinib; Narrow Therapeutic Index Drug (NTID); Receptor tyrosine kinase (RTK); Sunitinib; Toxicity; Tyrosine kinase inhibitor (TKI); Cell viability; ALL; acute lymphoblastic leukemia; AUC; area under the curve; b.i.d.; twice daily
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
Keywords: دو بار در روز; efficacy; Janus kinase inhibitor; long-term; psoriasis; randomized controlled trial; safety; tofacitinib; AE; adverse event; BID; twice daily; CI; confidence interval; HZ; herpes zoster; IR; incidence rate; LTE; long-term extension; NMSC; nonmelanoma skin
Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment
Keywords: دو بار در روز; CRTH2 antagonist; Asthma; Inhaled corticosteroid; ACQ; Asthma Control Questionnaire; AQLQ; Asthma Quality of Life Questionnaire; AUC; area under the curve; bid; twice daily; CI; confidence interval; CRTH2; chemoattractant receptor homologous molecule on T
Research ArticleRandomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
Keywords: دو بار در روز; HCV; hepatitis C virus; PegIFN; peginterferon; danoprevir/r; ritonavir-boosted danoprevir; IFN; interferon; RNA; ribonucleic acid; SVR24; sustained virological response 24Â weeks after end-of-treatment; G; genotype; bid; twice daily; ACTG; AIDS Clinical T
Research ArticleSTARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection
Keywords: دو بار در روز; HCV; hepatitis C virus; PI; protease inhibitor; PegIFN; peginterferon; RBV; ribavirin; SVR; sustained virologic response; DDI; drug-drug interaction; BID; twice daily; ETS; early treatment success; TD; target detected; TND; target not detected; EVR; ear